Influenza vaccine effectiveness against hospitalizations in children and older adults—Data from South America, 2013–2017. A test negative design

Autor: Carmen Sofia Arriola, Nathalie El Omeiri, Eduardo Azziz-Baumgartner, Mark G. Thompson, Viviana Sotomayor-Proschle, Rodrigo A. Fasce, Martha Von Horoch, José Enrique Carrizo Olalla, Walquíria Aparecida Ferreira de Almeida, Jacqueline Palacios, Rakhee Palekar, Paula Couto, Miguel Descalzo, Alba María Ropero-Álvarez, Cecilia Gonzalez, Sergio Loayza, Natalia Vergara, Patricia Bustos, Winston Andrade, Carla Magda S. Domingues, Ernesto Issac Montenegro Renoiner, Érica Tatiane da Silva, Swamy Lima Palmeira, Daiana Araujo da Silva, Ana Carolina de Lacerda Sousa, Marilda Mendonça Siqueira, Cynthia Vazquez, Silvia Battaglia, Carla Vizzotti, Elsa Baumeister, Carlos Giovacchini, Nathalia Katz, Oscar Pacheco, Juliana Barbosa, Diana Malo, Paola Pulido, Diego Garcia, Consuelo Pinzón
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Zdroj: Vaccine: X, Vol 3, Iss , Pp - (2019)
Druh dokumentu: article
ISSN: 2590-1362
DOI: 10.1016/j.jvacx.2019.100047
Popis: Background: In 2013, the Pan American Health Organization established a multi-site, multi-country network to evaluate influenza vaccine effectiveness (VE). We pooled data from five consecutive seasons in five countries to conduct an analysis of southern hemisphere VE against laboratory-confirmed influenza hospitalizations in young children and older adults. Methods: We used a test-negative design to estimate VE against laboratory-confirmed influenza in hospitalized young children (aged 6─24 months) and older adults (aged ≥60 years) in Argentina, Brazil, Chile, Colombia, and Paraguay. Following country-specific influenza surveillance protocol, hospitalized persons with severe acute respiratory infections (SARI) at 48 sentinel hospitals (March 2013–December 2017) were tested for influenza virus infection by rRT-PCR. VE was estimated for young children and older adults using logistic random effects models accounting for cluster (country), adjusting for sex, age (months for children, and age-in-year categories for adults), calendar year, country, preexisting conditions, month of illness onset and prior vaccination as an effect modifier for the analysis in adults. Results: We included 8426 SARI cases (2389 children and 6037 adults) in the VE analyses. Among young children, VE against SARI hospitalization associated with any influenza virus was 43% (95%CI: 33%, 51%) for children who received two doses, but was 20% (95%CI: −16%, 45%) and not statistically significant for those who received one dose in a given season. Among older adults, overall VE against SARI hospitalization associated with any influenza virus was 41% (95%CI: 28%, 52%), 45% (95%CI: 34%, 53%) against A(H3N2), 40% (95%CI: 18%, 56%) against A(H1N1)pdm09, and 20% (95%CI: −40%, 54%) against influenza B viruses. Conclusions: Our results suggest that over the five-year study period, influenza vaccination programs in five South American countries prevented more than one-third of laboratory confirmed influenza-associated hospitalizations in young children receiving the recommended two doses and vaccinated older adults. Keywords: Influenza vaccine effectiveness, Children, Adults, Southern hemisphere, Latin America, Severe acute respiratory infections, Test-negative case-control design, Hospitalizations
Databáze: Directory of Open Access Journals